ReviewWorld journal of gastroenterology2014
Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma.Hepatology (Baltimore, Md.) · 2015Pooled it
- The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis.PloS one · 2015Pooled it
- Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B.World journal of gastroenterology · 2021Trial
- Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.BMC gastroenterology · 2019Trial
- HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients.Virology journal · 2016Trial
- Misinformation and Profitability of Hepatitis B Virus Claims on Instagram: Formative Cross-Sectional Study.JMIR formative research · 2026Article
- Xanthine oxidase inhibition by medicinal plants mitigates tenofovir-induced nephrotoxicity: a comprehensive computational and experimental study.Frontiers in pharmacology · 2026Article
- Rapid Enzymatic Assay for Antiretroviral Drug Monitoring Using CRISPR-Cas12a-Enabled Readout.ACS synthetic biology · 2025Article
- Article
- Trends and future projections of liver cancer incidence in Hong Kong: a population-based study.Archives of public health = Archives belges de sante publique · 2023Article
- Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation.The Lancet regional health. Western Pacific · 2023Article
- Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers.Frontiers in pharmacology · 2023Article
- Increased liver stiffness promotes hepatitis B progression by impairing innate immunity in CCl4-induced fibrotic HBVFrontiers in immunology · 2023Article
- Value of multimodal MRI radiomics and machine learning in predicting staging liver fibrosis and grading inflammatory activity.The British journal of radiology · 2023Article
- Hepatitis B infection status among South Africans attending public health facilities over a five-year period: 2015 to 2019.PLOS global public health · 2023Article
- Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches.International journal of molecular sciences · 2022Review
- Development of pH-Sensitive Chitosan-Polymers · 2021Article
- Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure.Hepatology international · 2021Article
- A computational multi-targeting approach for drug repositioning for psoriasis treatment.BMC complementary medicine and therapies · 2021Article
- Noninvasive DW-MRI metrics for staging hepatic fibrosis and grading inflammatory activity in patients with chronic hepatitis B.Abdominal radiology (New York) · 2021Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B (CHB) virus infection is a global public health problem, affecting more than 400 million people worldwide. The clinical spectrum is wide, ranging from a subclinical inactive carrier state, to progressive chronic hepatitis, cirrhosis, decompensation, and hepatocellular carcinoma. However, complications of hepatitis B virus (HBV)-related chronic liver disease may be reduced by viral suppression. Current international guidelines recommend first-line treatment of CHB infection with pegylated interferon, entecavir, or tenofovir, but the optimal treatment for an individual patient is controversial. The indications for treatment are contentious, and increasing evidence suggests that HBV genotyping, as well as serial on-treatment measurements of hepatitis B surface antigen and HBV DNA kinetics should be used to predict antiviral treatment response. The likelihood of achieving a sustained virological response is also increased by extending treatment duration, and using combination therapy. Hence the paradigm for treatment of CHB is constantly evolving. This article summarizes the different indications for treatment, and systematically reviews the evidence for the efficacy of various antiviral agents. It further discusses the shortcomings of current guidelines, use of rescue therapy in drug-resistant strains of HBV, and highlights the promising clinical trials for emerging therapies in the pipeline. This concise overview presents an updated practical approach to guide the clinical management of CHB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.